Co-Diagnostics, Inc.
  • About
    • Locations
      • Salt Lake City, Utah
      • Gujarat, India
    • CoSara Diagnostics Private Limited
    • Videos & Multimedia
    • Management
  • PRODUCTS
    • Diagnostic Solutions
      • Logix Smart™ MTB
      • Logix Smart™ Zika
      • Logix Smart™ ZDC
      • Logix Smart™ COVID-19 (FDA EUA)
      • Logix Smart™ SARS-CoV-2 (RdRp/E)
      • Logix Smart™ SARS-CoV-2 DS
      • Logix Smart™ ABC
    • Research Solutions
      • Logix Smart 2019-nCoV
    • Vector Control Solutions
    • Agricultural Solutions
    • Equipment
    • CoPrimers™/CODX™ Design Services
  • APPLICATIONS
    • Screenings & Detection
    • Multiplexing
    • SNP Detection
    • Next-Gen Sequencing
    • Liquid Biopsy
  • TECHNOLOGY
    • What is PCR?
    • History
    • CoPrimers™
    • RapidProbes™
    • Hot Start
    • CoPrimer Design™ Process
  • Newsroom
    • Press Releases
    • In The News
    • Media Resources
      • RSS
  • INVESTORS
    • Events-Webcasts
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
    • SEC filings
    • Financial Information
      • Key Ratios
    • Corporate Governance
      • Board Committees
    • Investor Resources
  • Resources
    • Terms And Conditions For Sales
    • Instructions For Use
    • Safety Data Sheets
    • Instructional Videos
    • Troubleshooting
    • Publications
  • CONTACT
Select Page

Co-Diagnostics Inc Announces Successful Initial Verification of Novel Coronavirus Test

by Co-Diagnostics | Jan 31, 2020 | News Release

Components of recently designed novel coronavirus assay have successfully passed initial verification Salt Lake City, Utah – January 30, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of...

Co-Diagnostics Inc CEO Interviewed on Fox Business with Maria Bartiromo as Coronavirus Concerns Rise

by Co-Diagnostics | Jan 30, 2020 | News Release

Interviews on Fox Business and other programs discussed issues surrounding the novel strain of the coronavirus and the Company’s plan to provide a diagnostic solution  Salt Lake City, Utah – January 30, 2020 – The CEO of Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular...

Co-Diagnostics Inc Featured in Article on BioWorld

by Co-Diagnostics | Jan 29, 2020 | News Release

Salt Lake City, Utah – January 29, 2020 – Co-Diagnostics, Inc. (Nasdaq: CODX), was recently featured in an article on BioWorld titled “Co-Diagnostics completes critical step in developing coronavirus diagnostic.” The article discussed completion of principle...

Co-Diagnostics Announces Closing of $5 Million Registered Direct Offering Priced At-the-Market

by Co-Diagnostics | Jan 28, 2020 | News Release

Salt Lake City, Utah – January 28, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the closing of its previously announced...

Co-Diagnostics Inc CEO Discusses Novel Coronavirus with CNBC Squawk Box Asia

by Co-Diagnostics | Jan 28, 2020 | News Release

Interview covered method of transmission, importance of accurate diagnostic tools, and the Company diagnostic announced last week Salt Lake City, Utah – January 28, 2020 – The CEO of Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique,...
« Older Entries

Follow us on Facebook

https://www.facebook.com/codiagnostics/
Have any questions?   +1 (1) 801 438 1036   info@codiagnostics.com
Have questions? Need assistance?

Let’s chat.

We’re here with answers. Please fill out the forms below, and we will contact you shortly.

Site Terms and Conditions
Privacy Policy

Co-Diagnostics, Inc.

2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States

1 (801) 438-1036

info@codiagnostics.com

Company

About

Applications

Technology

Products

 

News Room

Investors

Contact